Introducing P&T TV
We would like to encourage you to send us your own short videos about your P&T committee experiences. Tell us what topics are hot at your committee meetings and your video might get posted to this site. All entries will be considered for posting. Contact Editor Sonja Sherritze, at 267-685-2779 or by email at email@example.com.
We would also like your feedback. So take a tour around the site and let us know what you think. Thanks for reading P&T, and for visiting PTCommunity. Remember, P&T is the place to be!
Phase 2 Study of Intralesional PV-10 (Rose Bengal) in Metastatic Melanoma
Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology at St. Luke’s University Health Network in Bethlehem, PA, and Professor of Medicine at Temple University in Philadelphia, PA, discusses several scenarios in which PV-10 might be used if it is ultimately approved for patients with advanced melanoma.
Overview of the LUME-lung 1, Phase 3 Trial
Martin Reck, MD, PhD, says that combination treatment with nintendanib was significantly superior to docetaxel monotherapy in non-small-cell lung cancer after one chemotherapy regimen (LUME-lung 1, Phase 3).
Inhibiting the mTOR Pathway in Trastuzumab-Resistant, HER-2-Positive Advanced Breast Cancer Patients: BOLERO-3, Phase 3
Ruth O’Regan, MD, says that the combination of everolimus plus vinorelbine and trastuzumab may be considered an appropriate option in trastuzumab-resistant, HER-2-positive advanced breast cancer (BOLERO-3, Phase 3).
Looking for Predictive Factors in Advanced Breast Cancer: BOLERO-2, Phase 3
Hope Rugo, MD, discusses the direction of current research into biologic agents for the treatment of advanced breast cancer at the American Society of Clinical Oncology meeting June 3, 2013, in Chicago.
Coverage Expansion Means More Regulations
Get ready for a slew of regulatory changes as the Affordable Care Act is implemented, warns F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare. As 2014 approaches, keep an eye out on whatâ€™s coming from the Department of Health and Human Services, the Department of Labor, and the Internal Revenue Service.
Beware of the Drug Shortage Domino Effect
Drug shortages might cause more drug substitutions which, in turn, could increase the chances of adverse events and the legal ramifications that go with them, says F. Randy Vogenberg, RPh, PhD. Newly created accountable care organizations need to be wary.
More Will Be Expected of Pharmacists
F. Randy Vogenberg, RPh, PhD, a member of P&T’s Editorial Board, says that in the fixed reimbursement system under health reform, pharmacists will need to balance clinical and economic considerations. The less expensive drug might not always be the answer.
Who Will Pay for High-Cost Biologics?
Insurance coverage was never meant to handle new pharmaceutical breakthroughs on the radar — breakthroughs that can cost anywhere from $90,000 to $300,000 a year per patient, says F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare and a member of P&T’s Editorial Board. There will be pressure on everybody to find a way to somehow control these costs.
What Changes are Coming for P&T Committees as a Result of the Affordable Care Act?
P&T committees will have to consider the economic fallout from their decisions as health reform advances, says F. Randy Vogenberg, RPh, PhD. That will be an adjustment.